Introduction
Leading pharmaceutical company receives USFDA approval for Verapamil Hydrochloride Extended-Release Tablets 120 mg, 180 mg, 240 mg, produced at Baddi facility, used to treat high blood pressure and heart-related risks.
Also Read: RMC Switchgears: Stock rises after bagging ₹42.23 Cr order in Rajasthan
Share price movement of Zydus Lifesciences
On November 25, 2025, Zydus Lifesciences Ltd opened at ₹927.25, up 0.07% from its previous close of ₹926.60. The stock reached a high of ₹935.00 (0.88%) and a low of ₹922.80. By 4:01 PM, it traded at ₹927.50, a 0.10% increase, with a market cap of ₹93,328.20 crore.
Zydus Receives USFDA Approval for Verapamil
Zydus Lifesciences Limited received final USFDA approval for Verapamil Hydrochloride Extended-Release Tablets USP in 120 mg, 180 mg, and 240 mg strengths. The drug treats high blood pressure.
The tablets reduce risks of serious heart problems, including strokes and heart attacks. Production will take place at Zydus Lifesciences’ Baddi facility in Himachal Pradesh.
Verapamil Hydrochloride Extended-Release Tablets had annual U.S. sales of USD 24.5 million. Zydus now holds 428 approvals and has filed 487 ANDAs since FY 2003-04.
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd delivered a -0.19% return over the past week, it gained 0.21% in the past six months. The stock declined by -3.91% over the past year.
Also Read: Embassy Developments: Stock jumps on announcement to launch 6 projects worth ₹10,300 Cr
Shareholding pattern of Zydus Lifesciences
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.30% | 7.10% | 7.30% |
| DII | 10.90% | 11.10% | 11% |
| Public | 6.80% | 6.70% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE), formed in 1995, focuses on healthcare innovation, addressing unmet medical needs, and has grown from ₹250 crore turnover to over ₹14,253 crore in FY20.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: Zydus Lifesciences Ltd share price rose after receiving USFDA approval for Verapamil Hydrochloride Extended-Release Tablets, produced at Baddi facility, USA sales USD 24.5 million.
A: Zydus Lifesciences Ltd specializes in healthcare and pharmaceutical products, focusing on innovation, unmet medical needs, and global community health initiatives.
A: The 52-week high of Zydus Lifesciences Ltd stock is ₹1,059.00, and the 52-week low is ₹797.05.


